HCW Biologics regains Nasdaq bid price compliance, plans reverse split

HCW Biologics Inc. (Nasdaq: HCWB) announced that the Nasdaq Hearings Panel found the company regained compliance with Nasdaq Listing Rule 5550(a)(2), known as the Bid Price Rule, on June 29, 2026.

The panel's determination follows a decision letter dated May 29, 2026. The company is now subject to a mandatory monitoring period through June 17, 2027.

To maintain long-term compliance with the Bid Price Rule, the Miramar, Fla.-based clinical-stage biopharmaceutical company said it will execute a one-for-six reverse stock split on June 30, 2026.

The company stated it is now compliant with all continued listing rules for Nasdaq.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Cigna Corp. (CI) Declares $1.56 Quarterly Dividend; 2.2% Yield
• Oceaneering (OII) Tops Q2 EPS by 19c